To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.

Bill 118 hr 6400, also known as the "Medicare Biosimilar Payment Extension Act," aims to make changes to the Medicare program in order to extend eligibility for certain payment increases for biosimilar biological products. Biosimilar biological products are medications that are highly similar to already approved biological products, but are typically more affordable.

The bill seeks to amend title XVIII of the Social Security Act, which governs the Medicare program, in order to ensure that biosimilar biological products are eligible for payment increases. This would help to incentivize the development and use of these more affordable medications, ultimately benefiting Medicare beneficiaries by providing them with more cost-effective treatment options.

By extending eligibility for payment increases for biosimilar biological products, the bill aims to promote competition in the pharmaceutical industry, drive down drug costs, and improve access to important medications for Medicare beneficiaries. This legislation is important for ensuring that Medicare remains sustainable and effective in providing quality healthcare to its beneficiaries. Overall, the "Medicare Biosimilar Payment Extension Act" is a crucial piece of legislation that aims to improve the Medicare program by expanding access to affordable medications for beneficiaries.